Myrto T Samara1, Adriani Nikolakopoulou2, Georgia Salanti2, Stefan Leucht1. 1. Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Ismaningerstr, Munich, Germany. 2. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland.
Abstract
OBJECTIVE: An important clinical question is how many patients with acute schizophrenia do not respond to antipsychotics despite being treated for adequate time and with an effective dose. However, up to date, the exact extent of the phenomenon remains unclear. METHODS: We calculated the nonresponse and nonremission percentages using individual patient data from 16 randomized controlled trials (RCTs). Six thousand two hundred twenty-one patients were assigned to one antipsychotic (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone) at an adequate dose; the response was assessed at 4-6 weeks. As various definitions of nonresponse have been used in the literature, we applied 4 different cut-offs covering the whole range of percent Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) reduction (≤0%, <25%, <50%, <75%).For symptomatic remission, we used the definition proposed by Andreasen without employing the time criterion. RESULTS: The overall nonresponse for the cut-off of ≤0% PANSS/BPRS reduction was 19.8% (18.8%-20.8%); for the cut-off of <25% reduction it was 43% (41.7%-44.3%); for the cut-off of <50% reduction it was 66.5% (65.3%-67.8%); and for the cut-off of <75% reduction it was 87% (86%-87.9%). The overall percentage of no symptomatic remission was 66.9% (65.7%-68.1%). Earlier onset of illness, lower baseline severity and the antipsychotic used were significantly associated with higher nonresponse percentages. CONCLUSIONS: Nonresponse and nonremission percentages were notably high. Nevertheless, the patients in our analysis could represent a negative selection since they came from short-term RCTs and could have been treated before study inclusion; thus, further response may not have been observed. Observational studies on this important question are needed.
OBJECTIVE: An important clinical question is how many patients with acute schizophrenia do not respond to antipsychotics despite being treated for adequate time and with an effective dose. However, up to date, the exact extent of the phenomenon remains unclear. METHODS: We calculated the nonresponse and nonremission percentages using individual patient data from 16 randomized controlled trials (RCTs). Six thousand two hundred twenty-one patients were assigned to one antipsychotic (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone) at an adequate dose; the response was assessed at 4-6 weeks. As various definitions of nonresponse have been used in the literature, we applied 4 different cut-offs covering the whole range of percent Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) reduction (≤0%, <25%, <50%, <75%).For symptomatic remission, we used the definition proposed by Andreasen without employing the time criterion. RESULTS: The overall nonresponse for the cut-off of ≤0% PANSS/BPRS reduction was 19.8% (18.8%-20.8%); for the cut-off of <25% reduction it was 43% (41.7%-44.3%); for the cut-off of <50% reduction it was 66.5% (65.3%-67.8%); and for the cut-off of <75% reduction it was 87% (86%-87.9%). The overall percentage of no symptomatic remission was 66.9% (65.7%-68.1%). Earlier onset of illness, lower baseline severity and the antipsychotic used were significantly associated with higher nonresponse percentages. CONCLUSIONS: Nonresponse and nonremission percentages were notably high. Nevertheless, the patients in our analysis could represent a negative selection since they came from short-term RCTs and could have been treated before study inclusion; thus, further response may not have been observed. Observational studies on this important question are needed.
Authors: Bruce J Kinon; Douglas L Noordsy; Hong Liu-Seifert; Angela H Gulliver; Haya Ascher-Svanum; Sara Kollack-Walker Journal: J Clin Psychopharmacol Date: 2006-10 Impact factor: 3.153
Authors: Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf Engel Journal: Br J Psychiatry Date: 2005-10 Impact factor: 9.319
Authors: Donald C Goff; Peter Falkai; W Wolfgang Fleischhacker; Ragy R Girgis; Rene M Kahn; Hiroyuki Uchida; Jingping Zhao; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2017-05-05 Impact factor: 18.112
Authors: Stefan Leucht; Andrea Cipriani; Loukia Spineli; Dimitris Mavridis; Deniz Orey; Franziska Richter; Myrto Samara; Corrado Barbui; Rolf R Engel; John R Geddes; Werner Kissling; Marko Paul Stapf; Bettina Lässig; Georgia Salanti; John M Davis Journal: Lancet Date: 2013-06-27 Impact factor: 79.321
Authors: Kate Merritt; Ana Catalan; Samuel Cowley; Arsime Demjaha; Matthew Taylor; Philip McGuire; Ruth Cooper; Paul Morrison Journal: J Psychopharmacol Date: 2020-05-21 Impact factor: 4.153
Authors: David T Turner; Mirjam Reijnders; Mark van der Gaag; Eirini Karyotaki; Lucia R Valmaggia; Steffen Moritz; Tania Lecomte; Douglas Turkington; Rafael Penadés; Helio Elkis; Corinne Cather; Frances Shawyer; Kieron O'Connor; Zhan-Jiang Li; Eliza Martha de Paiva Barretto; Pim Cuijpers Journal: Front Psychiatry Date: 2020-05-05 Impact factor: 4.157